Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):173-185
Beta-lactams are the most commonly used class of antimicrobial agents for the treatment of community-acquired and nosocomial infections. One of the resistance mechanisms for this class is a production of beta-lactamases. To overcome this problem, the beta-lactamases inhibitors - clavulanic acid, sulbactam, and tazobactam, - have been developed. Currently, there are several combinations of beta-lactams/beta-lactam inhibitors are available on pharmaceutical market. Most of them have an aminopenicillin as antibiotic component. This paper provides an overview of pharmacology, microbiological and clinical data concerning a new beta-lactam/beta-lactamase inhibitor combination – amoxicillin/sulbactam.